中国实用神经疾病杂志2018，Vol.21Issue(22)：2487-2493,7.DOI:10.12083/SYSJ.2018.22.528
人血白蛋白治疗急性缺血性脑卒中疗效及安全性系统评价
Efficacy and safety of human serum albumin in the treatment of acute ischemic stroke: A systematic review
摘要
Abstract
Objective To evaluate efficacy and safety of human serum albumin in the treatment of acute ischemic stroke.Methods Retrieved from PubMed, Web of Science, The Cochrane Library, Clinical Trials, CNKI and Wanfang database.Randomized controlled trials (RCTS) about human serum albumin in acute ischemic stroke were collected.The quality of RCTs was evaluated by Cochrane System Evaluator Manual 5.1.0.The 14-day NIHSS score, 14-day and 90-day efficiencyand the incidence of adverse reactionswere analyzed by Meta-analysis with Rev Man 5. 3 statistical software.Results A total of 8 RCTs were includedwith 1946 patients.The National Institutes of Health Stroke Scale at 14 days (MD =-2. 74, 95％ CI-3. 89-0. 16, Z = 4. 7, P＜0. 000 01) and response rate at 14 days (OR = 2. 73, 95％ CI 1. 77-4. 22, Z = 4. 55, P ＜ 0. 000 01) in trial group were significantly better than control group, but there was no statistical difference in the response rate at 90 days (OR = 1. 85, 95％ CI 0. 76-4. 6, Z = 1. 36, P = 0. 18).The incidence of Pulmonary edema/Congestive heart failure within 48h (OR = 6. 43, 95％ CI 4. 83-30. 84, Z = 6. 27, P＜0. 000 01) in trial group was significantly higher than control group.Conclusion The effectiveness of HSA in the treatment of acute ischemic stroke needs more clinical trialsbased on NIHSS scores, time of HSA administration, and dose of HSA; the major adverse effect of human serum albumin is pulmonary edema/congestive heart failure.关键词
人血白蛋白/急性缺血性脑卒中/急性脑梗死/安全性/系统评价Key words
Human serum albumin/Acute ischemic stroke/Acute cerebral infarction/Safety/Systematic review分类
医药卫生引用本文复制引用
李艳艳,李军伟,蒋超,赵峻,王延虹,时磊..人血白蛋白治疗急性缺血性脑卒中疗效及安全性系统评价[J].中国实用神经疾病杂志,2018,21(22):2487-2493,7.基金项目
河南省科技攻关计划项目 (编号:172102310265) （编号:172102310265）
